DT&CRO CO., Ltd. (KOSDAQ:383930)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,865.00
-290.00 (-9.19%)
At close: Feb 27, 2026
-61.44%
Market Cap 36.31B
Revenue (ttm) 44.36B
Net Income (ttm) 4.17B
Shares Out 12.78M
EPS (ttm) -95.20
PE Ratio 8.70
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 219,058
Average Volume 190,156
Open 3,130.00
Previous Close 3,155.00
Day's Range 2,820.00 - 3,220.00
52-Week Range 2,250.00 - 9,370.00
Beta 2.27
RSI 52.76
Earnings Date n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 383930
Full Company Profile

Financial Performance

In 2024, DT&CRO CO.'s revenue was 35.97 billion, an increase of 35.30% compared to the previous year's 26.59 billion. Losses were -2.00 billion, -87.98% less than in 2023.

Financial Statements

News

There is no news available yet.